Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 2:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Surgical Resection Clear all
Completed No phase listed Observational

Study of Resection Combined With Stereotactic Radiosurgery for 1 to 3 Brain Metastases

NCT00904553
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
Novalis Shaped Beam Surgery
Radiation
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 11, 2026, 2:35 PM EDT
Completed Phase 2 Interventional

CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma

NCT04727242
View directory record Official record
Conditions
LMS - Leiomyosarcoma, Uterine Leiomyosarcoma
Interventions
Gemcitabine, Dacarbazine, Cytoreductive Surgery, Functional Assessment of Cancer Therapy (FACT) G questionnaire, Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan, Gadolinium
Drug · Procedure · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 11, 2026, 2:35 PM EDT
Terminated Phase 3 Interventional

Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection

NCT00014651
View directory record Official record
Conditions
Pancreatic Cancer, Perioperative/Postoperative Complications
Interventions
vapreotide, conventional surgery
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
18
States / cities
Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Sep 11, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer

NCT00033657
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
cisplatin, irinotecan hydrochloride, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
23
States / cities
Denver, Colorado • Newark, Delaware • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 11, 2026, 2:35 PM EDT
Recruiting Phase 2 Interventional

Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)

NCT06088381
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Experimental Observation, Observation per Standard of Care, Adjuvant Treatment per Standard of Care, Circulating Tumor DNA test (ctDNA test)
Other · Radiation · Diagnostic Test
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 11, 2026, 2:35 PM EDT
Not yet recruiting Phase 2 Interventional

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

NCT07612007
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Darizmetinib, Embolization Therapy, Hepatectomy, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 11, 2026, 2:35 PM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate the Use of Supine MRI Images in Breast Conserving Surgery

NCT01929395
View directory record Official record
Conditions
Breast Cancer
Interventions
Supine MRI
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 11, 2026, 2:35 PM EDT
Recruiting Phase 2 Interventional

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

NCT04317534
View directory record Official record
Conditions
NSCLC, Stage I
Interventions
Pembrolizumab
Drug
Lead sponsor
Greg Durm, MD
Other
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
13
States / cities
Tampa, Florida • Chicago, Illinois • Indianapolis, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 11, 2026, 2:35 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

ProACT Post-Approval Study

NCT03767595
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
ProACT Adjustable Continence Therapy for Men
Device
Lead sponsor
Uromedica
Industry
Eligibility
50 Years and older · Male only
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
6
States / cities
Denver, Colorado • Gainesville, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 11, 2026, 2:35 PM EDT
Terminated Phase 1 Interventional

Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection

NCT04608812
View directory record Official record
Conditions
Glioma, Malignant, High Grade Glioma, Glioblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
OS2966, Gadoteridol
Drug
Lead sponsor
OncoSynergy, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Sep 11, 2026, 2:35 PM EDT
Withdrawn Phase 2 Interventional

Single vs Multi-fraction SRS Patients on Immunotherapy

NCT04427228
View directory record Official record
Conditions
Brain Cancer, Brain Metastases
Interventions
Radiosurgery Single Treatment, Radiosurgery Three Treatments
Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 11, 2026, 2:35 PM EDT
Active, not recruiting Not applicable Interventional

Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation

NCT02658565
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Lymphadenectomy
Procedure
Lead sponsor
Frederick R. Ueland, M.D.
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 11, 2026, 2:35 PM EDT
Completed Not applicable Interventional Results available

Comparative Efficacy of the Masquelet Versus Titanium Mesh Cage Techniques for the Treatment of Large Long Bone Defects

NCT02015390
View directory record Official record
Conditions
Segmental Long Bone Defects
Interventions
Autogenous RIA bone grafting, Allogeneic bone grafting
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 99 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Sep 11, 2026, 2:35 PM EDT
Completed Phase 2 Interventional

Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery

NCT00336960
View directory record Official record
Conditions
Colorectal Cancer
Interventions
celecoxib, fluorouracil, conventional surgery, radiation therapy, tumor biopsy, laboratory biomarker analysis
Drug · Procedure · Radiation + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 11, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Results available

Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy

NCT04415944
View directory record Official record
Conditions
Ovarian Epithelial Cancer Stage I, Ovarian Epithelial Cancer Stage II, Ovarian Epithelial Cancer Stage III, Stage I Fallopian Tube Cancer, Stage II Fallopian Tube Cancer, Stage III Fallopian Tube Cancer, Peritoneal Carcinoma
Interventions
Second look laparoscopy reassessment surgery (SLLRS), HIPEC with Carboplatin, FACT-O Quality of Life Questionnaire
Procedure · Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 11, 2026, 2:35 PM EDT
Terminated Phase 2 Interventional Results available

Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation

NCT00659334
View directory record Official record
Conditions
Brain Neoplasms
Interventions
Ferumoxtran-10 (Combidex), Neurosurgery
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
5 Years to 75 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 11, 2026, 2:35 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function

NCT01280344
View directory record Official record
Conditions
Gastrointestinal Dysmotility
Interventions
Saline Solution for Injection, Ipamorelin
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
45
States / cities
Florence, Alabama • Sheffield, Alabama • Fountain Valley, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 11, 2026, 2:35 PM EDT
Recruiting Phase 1 Interventional

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

NCT06186401
View directory record Official record
Conditions
EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Interventions
E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational), Leukapheresis, Surgical resection
Biological · Drug · Procedure
Lead sponsor
Hideho Okada, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 11, 2026, 2:35 PM EDT
Completed Phase 1 Interventional

Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

NCT02658981
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Recurrent Brain Neoplasm
Interventions
Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, Pharmacological Study, Laboratory Biomarker Analysis, Anti-CD137
Biological · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 11, 2026, 2:35 PM EDT
Active, not recruiting No phase listed Observational

Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer

NCT05183932
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
7
States / cities
Atlanta, Georgia • Urbana, Illinois • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 11, 2026, 2:35 PM EDT
Recruiting Phase 2 Interventional

Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstruction

NCT06831149
View directory record Official record
Conditions
Squamous Cell Carcinoma, Pharyngocutaneous Fistula
Interventions
Removal of pharyngeal mucosa with decreased perfusion will be performed, SPY-PHI, ICG (Indocyanine Green)
Procedure · Device · Drug
Lead sponsor
Matthew Spector
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 11, 2026, 2:35 PM EDT
Not listed Phase 3 Interventional

Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing

NCT02907385
View directory record Official record
Conditions
Rectal Cancer, Anastomotic Leak
Interventions
LifeSeal™ Kit
Device
Lead sponsor
LifeBond Ltd.
Industry
Eligibility
21 Years and older
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
23
States / cities
Los Angeles, California • Stanford, California • Florida City, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Sep 11, 2026, 2:35 PM EDT
Completed Early Phase 1 Interventional

Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT01504126
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v6 and v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Chemotherapy, Propranolol Hydrochloride, Quality-of-Life Assessment, Therapeutic Conventional Surgery
Drug · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
7
States / cities
Gilbert, Arizona • Houston, Texas • Sugar Land, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Sep 11, 2026, 2:35 PM EDT
Recruiting Not applicable Interventional

Pre-operative Nutrition for Elective Resection Surgery in Inflammatory Bowel Disease

NCT06309017
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Nutrition specialist, Ensure Surgery Immunonutrition shakes
Other · Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 11, 2026, 2:35 PM EDT